Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER_GOV 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Uterine Cervical Neoplasms 3Refractory Solid Tumors 1Ovarian Neoplasms 1Locally Advanced Breast Cancer 1

Interventions

Cisplatin 6Radiotherapy 4Hydralazine 3Gemcitabine 3Valproic Acid 2Probiotics 2Paclitaxel 2Drug Therapy 2Brachytherapy 2spartalizumab 1nimotuzumab 1belotecan 1apatinib 1Therapeutics 1Surgical Procedures, Operative 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Proto-Oncogene Proteins c-raf 1Neoadjuvant Therapy 1Nelfinavir 1Mobile Health Units 1Magnetic Resonance Spectroscopy 1Magnesium 1Injections 1Immune Checkpoint Inhibitors 1Hysteroscopy 1Heart Rate 1Fatty Acids, Omega-3 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER_GOV × Uterine Cervical Neoplasms × Hydralazine × Clear all
NCT02446652 2025-05-29

Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

National Institute of Cancerología

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT00532818 2009-03-30

Hydralazine Valproate for Cervical Cancer

National Institute of Cancerología

Phase 3 Unknown
143 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT00404326 2006-11-28

Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer

National Institute of Cancerología

Phase 2 Completed
18 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡